Why the study?
Pre-existing myocardial fibrosis before AVR is a major cause of postoperative HF, and CT-ECV may enable risk stratification in patients with severe AS scheduled for TAVR or SAVR.
Does computed tomography extracellular volume (CT-ECV) predict all-cause mortality and heart failure hospitalization in patients with severe aortic stenosis scheduled for AVR?
Does computed tomography extracellular volume (CT-ECV) predict all-cause mortality and heart failure hospitalization in patients with severe aortic stenosis scheduled for AVR?
CT-ECV may be a useful prognostic tool to predict postoperative adverse events in patients with severe aortic stenosis undergoing AVR.
CT-ECV may refine risk stratification before AVR in severe AS; extends prognostic evidence but leaves open prospective validation and clinical adoption.
Aims: Pre-existing myocardial fibrosis before aortic valve replacement (AVR) is a major cause of postoperative heart failure (HF). Evaluation of fibrosis by computed tomography extracellular volume (CT-ECV) may allow risk stratification for patients with severe aortic stenosis (AS) scheduled for transaortic AVR (TAVR) or surgical AVR (SAVR). We performed a meta-analysis to determine the prognostic value of CT-ECV for the prediction of adverse events in patients with severe AS scheduled for AVR. Methods and results: < 0.001)]. Conclusion: Considering the high prognostic ability and versatility of CT-ECV, it may be used to predict postoperative adverse events in patients with severe AS who underwent AVR.
No takes yet. Share an insight, caveat, or question.
Kirigaya et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: